Halozyme: The Market May Be Underpricing The Second Growth Wave (NASDAQ:HALO)
· seekingalpha.com
Halozyme Therapeutics is evolving into a diversified, high-margin royalty platform. Click here to find out why HALO stock is a Buy.
Halozyme Therapeutics ( HALO ) still seems to be executing on what is now clearly a working compounding platform engine. You see, their business is structurally...